Published in Arthritis Res Ther on June 10, 2010
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis (2013) 0.91
[Diagnosis and therapy of early psoriatic arthritis]. Z Rheumatol (2012) 0.90
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics (2012) 0.84
Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open (2015) 0.77
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol (2016) 0.75
Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum (2010) 0.75
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol (1991) 2.89
Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med (1987) 2.80
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum (2004) 2.62
A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) (2003) 2.56
Rheumatic diseases: the effects of inflammation on bone. Immunol Rev (2005) 2.07
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum (2006) 1.73
Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum (1998) 1.73
Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) (2003) 1.69
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis (2006) 1.28
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol (2009) 1.26
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis (2006) 1.24
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum (2007) 1.21
A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis (2003) 1.20
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis (2008) 1.10
Psoriatic arthritis. Expert Opin Investig Drugs (2000) 1.04
Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum (2007) 1.00
Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis (2005) 0.96
Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum (2003) 0.83
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.71
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum (2004) 2.14
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum (2004) 1.94
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol (2006) 1.70
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum (2007) 1.68
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol (2009) 1.62
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum (2009) 1.54
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum (2002) 1.50
Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. J Rheumatol (2010) 1.49
Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol (2013) 1.46
Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol (2010) 1.46
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
MRI and quantification of draining lymph node function in inflammatory arthritis. Ann N Y Acad Sci (2007) 1.41
Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med (2006) 1.29
Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep (2006) 1.29
Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol (2005) 1.26
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol (2009) 1.26
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med (2014) 1.23
Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum (2007) 1.21
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res (2012) 1.19
CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther (2010) 1.17
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev (2013) 1.16
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol (2010) 1.16
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis (2012) 1.15
CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice. Arthritis Res Ther (2011) 1.15
Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2008) 1.14
RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens. J Cell Physiol (2010) 1.13
Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents. Postgrad Med (2004) 1.08
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. Arthritis Rheum (2013) 1.05
Outcome measures in psoriatic arthritis. J Rheumatol (2007) 1.05
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev (2012) 1.03
Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am (2009) 1.03
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) (2011) 1.02
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Psoriatic arthritis screening tools. J Rheumatol (2008) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther (2011) 1.00
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. J Immunol Methods (2008) 0.98
Autoimmunity and bone. Ann N Y Acad Sci (2006) 0.98
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol (2007) 0.98
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol (2006) 0.96
Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol (2011) 0.95
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol (2011) 0.95
Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol (2004) 0.95
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat (2006) 0.94
In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. J Physiol (2014) 0.93
Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol (2008) 0.93
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol (2012) 0.92
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl (2008) 0.91
Non-pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev (2013) 0.91
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol (2009) 0.91
Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum (2007) 0.91
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol (2014) 0.91
Outcome measures in psoriatic arthritis. J Rheumatol (2005) 0.88
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. J Rheumatol (2008) 0.87
Chronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol (2011) 0.87
Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol (2013) 0.86
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol (2011) 0.86
The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol (2009) 0.85
Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis Rheum (2010) 0.85
Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol (2009) 0.85
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis (2012) 0.85
Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis. J Bone Miner Res (2015) 0.84
Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol (2010) 0.84
Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol (2010) 0.84
Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg (2007) 0.84
Towards international guidelines for the management of psoriatic arthritis. J Rheumatol (2006) 0.84